Sidhartha Sinha

Dr. Sidhartha Sinha

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Cell Host & Microbe
Verified
Journal Article
Closed access
SSSidhartha Sinha
Sidhartha Sinha
YHYeneneh Haileselassie
Yeneneh Haileselassie
LNLinh P. Nguyen
Linh P. Nguyen
CTCarolina Tropini
Carolina Tropini
MWMin Wang
Min Wang
AHAida Habtezion
Aida Habtezion

19 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SRSamuel J. S. Rubin
Samuel J. S. Rubin
LBLawrence Bai
Lawrence Bai
YHYeneneh Haileselassie
Yeneneh Haileselassie
GGGotzone Garay
Gotzone Garay
CYChohee Yun
Chohee Yun
AHAida Habtezion
Aida Habtezion
Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis. Each disease is characterized by a diverse set of potential manifestations, which determine patients’ disease phenotype. Current understanding of phenotype determinants is limited, despite increasing prevalence and healthcare costs. Diagnosis and monitoring of disease requires invasive procedures, such as endoscopy and tissue biopsy. Here we report signatures of heterogeneity between disease diagnoses and phenotypes. Using mass cytometry, we analyze leukocyte subsets, characterize their function(s), and examine gut-homing molecule expression in blood and intestinal tissue from healthy and/or IBD subjects. Some signatures persist in IBD despite remission, and many signatures are highly represented by leukocytes that express gut trafficking molecules. Moreover, distinct systemic and local immune signatures suggest patterns of cell localization in disease. Our findings highlight the importance of gut tropic leukocytes in circulation and reveal that blood-based immune signatures differentiate clinically relevant subsets of IBD.

18 July 2012 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
SSSidhartha Sinha
Sidhartha Sinha
DHDavid Hofman
David Hofman
DSDavid L. Stoker
David L. Stoker
PFPeter J. Friend
Peter J. Friend
JPJan D. Poloniecki
Jan D. Poloniecki
PHPeter J. E. Holt
Peter J. E. Holt

10 March 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
YJYan Jiang
Yan Jiang
KJKarolin Jarr
Karolin Jarr
CLCosi Layton
Cosi Layton
CGChristopher Gardner
Christopher Gardner
JAJudith F. Ashouri
Judith F. Ashouri
SSSidhartha Sinha
Sidhartha Sinha
Despite being a focal issue to patients, the effect of diet on adult inflammatory bowel disease (IBD) remains underexplored with limited guidance. While promising clinical trials are currently underway, there is a need for further evidence-based recommendations. As such, we summarize the current evidence on various diets used in the treatment of IBD and also explore the potential applications of dietary data from related immune-mediated inflammatory diseases (IMIDs), such as rheumatoid arthritis and psoriasis, to provide additional information to inform IBD providers. To date, there have been multiple diets investigated as adjunctive therapy in IBD, but many associated studies are small, non-randomized, and not controlled. Mediterranean, vegetarian/vegan, and reduced-calorie/fasting diets have been studied and have shown some positive results in other IMIDs, which may suggest potential applicability to those with IBD, but larger, well-designed clinical trials are needed for further guidance. Gluten-free and low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)diets do not appear to have an impact on IBD disease activity, but low FODMAP may potentially be helpful for those with concurrent functional gastrointestinal symptoms. Specific carbohydrate diets have been mainly assessed in children but show some potential in small adult studies.

1 July 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
ECEthan Andrew Chi
Ethan Andrew Chi
GCGordon Chi
Gordon Chi
CTCheuk To Tsui
Cheuk To Tsui
YJYan Jiang
Yan Jiang
KJKarolin Jarr
Karolin Jarr
SSSidhartha Sinha
Sidhartha Sinha
It has been estimated that more than one-half of a general clinician’s workday can be spent interacting with electronic health records (EHRs).1-5 A survey of more than 500 primary care physicians6 reported that 62% of time devoted to each patient visit is spent referring to EHRs. Recently, a large study of approximately 100 million patient encounters across multiple medical specialties concluded that medical record review (ie, reviewing clinical results, patient data, and notes) accounted for the largest segment of time spent in the EHR, a trend also seen in inpatient medicine.7-9 Along with the increased adoption of EHRs, there has been a concomitant increase in the amount of data stored in these systems.10 Consequently, a theme of challenges experienced by EHR users is information overload, particularly because much of the EHR data (including new patient referral information) is often not pertinent to the particular patient encounter.11-14 Many factors—including overwhelming amounts of data—associated with EHR use have been contributors to physician dissatisfaction and burnout.15-18

20 July 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
PJPriyanka Jadhav
Priyanka Jadhav
YJYan Jiang
Yan Jiang
KJKarolin Jarr
Karolin Jarr
CLCosi Layton
Cosi Layton
JAJudith F. Ashouri
Judith F. Ashouri
SSSidhartha Sinha
Sidhartha Sinha
The microbiome is an important contributor to a variety of fundamental aspects of human health, including host metabolism, infection, and the immune response. Gut dysbiosis has been identified as a contributor to the errant immune response in a variety of immune-mediated inflammatory diseases (IMIDs), such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and psoriatic disease (psoriasis and psoriatic arthritis). Given this, probiotics and prebiotics have been investigated as therapeutic options in these disease states. In our review, we highlight the current evidence on prebiotics and probiotics as well as other supplements (such as fish oils, vitamin D, and curcumin) as therapies for IBD. Recommendations, however, regarding the specific use of such supplements in IBD have been lacking, particularly from professional societies, often due to study limitations related to small sample sizes and design heterogeneity. Hence, we additionally examine the literature on the use of prebiotics, probiotics, and other supplements in related IMIDs, namely RA and psoriasis/psoriatic arthritis, as these diseases share many approved therapeutic options with IBD. Based on these combined findings, we offer additional evidence that may help guide clinicians in their treatment of patients with IBD (and other IMIDs) and provide recommendations on potential next steps in therapeutic research in this area.